Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01334996 · ClinicalTrials.gov registry record

Use of Tamoxifen in Systemic Mastocytosis

A clinical trial of Systemic Mastocytosis, sponsored by Mayo Clinic.

Completed
Registry status
1
Enrollment target
1
Study location

NCT01334996 is a study of Systemic Mastocytosis that has completed, run by Mayo Clinic. The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01334996, a study of Systemic Mastocytosis, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
1 participants
Enrollment target
1
Study location

Study Summary

In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine will be excluded until these medications have been stopped.

Conditions Studied

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2005-02
Est. Completion 2019-08-28

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT01334996

The ClinicalTrials.gov registry entry for NCT01334996 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Mastocytosis appearing as the primary indexed condition, and to 0 interventions.

NCT01334996 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT01334996 about?

NCT01334996 is a clinical study titled "Use of Tamoxifen in Systemic Mastocytosis". In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release sym...

What is the current status of trial NCT01334996?

This trial is currently completed. The enrollment target is 1 participants. The study started on 2005-02. Estimated completion is 2019-08-28.

What conditions does trial NCT01334996 study?

This clinical trial studies the following conditions: Systemic Mastocytosis.

Who is sponsoring clinical trial NCT01334996?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01334996 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Systemic Mastocytosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.